Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma
✍ Scribed by Marie-Françoise Avril; Jean Bonneterre; Michelle Delaunay; Edouard Grosshans; Pierre Fumoleau; Lucien Israel; Roland Bugat; Moïse Namer; Didier Cupissol; Pierre Kerbrat; Philippe Montcuquet; Véronique Arcaute; Jean-Pierre Bizzari
- Publisher
- Springer
- Year
- 1990
- Tongue
- English
- Weight
- 709 KB
- Volume
- 27
- Category
- Article
- ISSN
- 0344-5704
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
BCNU, hydroxyurea, a n d imidazole carboxamide (DTIC) were administered to 89 patients with disseminated malignant melanoma. A response rate of 27% was observed. The addition of vincristine in another 89 patients did not significantly improve the response rate (30%). This includes patients who died
## Abstract The Southwest Oncology Group performed a randomized study comparing combination chemotherapy alone versus combination chemotherapy plus BCG versus DTIC plus BCG in the treatment of disseminated malignant melanoma. A 31% response rate was noted with combination chemotherapy alone, a 27%